Determination of the human cytochrome P450s involved in the metabolism of 2n -propylquinoline

References

• ARMSTRONG, R. N., 1999, Kinetic and chemical mechanism of epoxide hydrolase. Drug Metabolism and Disposition Reviews, 31, 71–86.
   PubMed Web of Science ®Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as tool for investigation of metabolic reaction catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 227, 321–332.
   Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1999, Role of cytochrome P-450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metabolism and Disposition, 27, 288–296.
   PubMed Web of Science ®Google Scholar
• BOYD, D. R., BUSHMAN, D. R., DAVIES, R. J. H., DORRITY, M. R. J., HAMILTON, L., JERINA, D. M., LEVIN, W., MCCULLOUGH, J. J., MCMORDIE, A. S., MALONE, J. F. and POTER, H. P., 1991, Absolute configurations of the arene oxide, trans-dihydrodiol and cis-dihydrodiol products resulting from metabolism of quinoline at the 5,6-bond. Tetrahedron Letters, 32, 2963–2966.
   Google Scholar
• BRADFORD, M. M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein—dye binding. Analytical Biochemistry, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• CARRIERE, V., BERTHOU, F., BAIRD, S., BELLOC, C., BEAUNE, P. and DE WAZIERS, I., 1996, Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6, 203–211.
   PubMedGoogle Scholar
• CHALMERS, D. and BROWN, S., 1987, Epoxide hydrolase expression in human and rodent established cell lines. Xenobiotica, 17, 71–77.
   PubMed Web of Science ®Google Scholar
• CHING, M. S., BLAKE, C. L., GHABRIAL, H., ELLIS, SW., LENNARD, M. S., TUCKER, G. T. and SMALLWOOD, R. A., 1995, Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochemical and Pharmacology, 50, 833–837.
   PubMed Web of Science ®Google Scholar
• DRAGACCI, S., THOMASSIN, J., MAGADALOU, J., SOUHAILI EL AMRI, H., BOISSEL, P. and SIEST, G., 1987, Properties of human hepatic UDP-glucuronosyl transferases. Relationship to other inducible enzymes in patients with cholestasis. European Journal of Clinical and Pharmacology, 32, 485–491.
   PubMed Web of Science ®Google Scholar
• EAGLING, V. A., TPA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• FOURNET, A., BARRIOS, A. A., MUNOZ, V., HOCQUEMILLER, R., CAVE, A. and BRUNETON, J., 1993, 2 SUBSTITUTED QUINOLINE ALKALOIDS AS POTENTIAL ANTILEISHMANIAL DRUGS. Antimicrobial Agents and Chemotherapy, 37, 859–863.
   PubMed Web of Science ®Google Scholar
• FOURNET, A., BARRIOS, A., MUNOZ, V., HOCQUEMILLER, R., ROBLOT, F., CAVE, A., RICHOMME, P. and BRUNETON, J., 1994a, Antiprotozoal activity of quinoline alkaloids isolated from Galipea longiflora, a Bolivian plant used as treatment for cutaneous leishmaniasis. Phytotherapy Research, 8, 174–178.
   Web of Science ®Google Scholar
• FOURNET, A., FERREIRA, M. E., ROJAS DE ARIAS, A., TORRES DE ORTIZ, S., FUENTES, S., NAKAYAMA, H., SCHININI, A. and HOCQUEMILLE R., 1996, In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 40, 2447–2451.
   PubMed Web of Science ®Google Scholar
• FOURNET, A., GANTIER, J. C., GAUTHERET, A., LEYSALLES, L., MUNOS, M. H., MAYRARGUE, J., MOSKOWITZ, H., CAVE, A. and HOCQUEMILLE R., 1994b, The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. Journal of Antimicrobial Chemotherapy, 33, 537–544.
   PubMed Web of Science ®Google Scholar
• FOURNET, A., MUNOS, V., MANJON, A. M., ANGELO, A., HOCQUEMILLER, R., CORTES, D., CAVE, A. and BRUNETON. J., 1998, Activite antiparasitaire d'alcaloïdes bisbenzylisoquinoleiques: Activite in vitro sur des promastigotes de trois souches de leishmania. Journal of Ethnopharmacology, 24, 327–335.
   Google Scholar
• GORSKI, J. C., HALL, S. D., JONES., D. R., VANDEN BRADEN, M. and WRIGHTON, SA., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP 3A) subfamily. Biochemical Pharmacology, 47, 1643–1653.
   Google Scholar
• HALL, S. D., GUENGERICH, F. P., BRANCH, R. A. and WILKINSON, G. R., 1987, Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 240, 216–222.
   PubMed Web of Science ®Google Scholar
• IGLARZ, M., BAUNE, B., GANTIER, J. C., HOCQUEMILLER, R. and FARINOTTI, R., 1998, Determination of 2n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography. Journal of Chromatography B, 714, 335–340.
   PubMedGoogle Scholar
• KINONEN, T., PASANEN, M., GYNTHER, J., Poso, A., JARVINEN, T., ALHAVA, E. and JUVONEN, R. O., 1995, Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. British Journal of Pharmacology, 116, 2625–2630.
   PubMed Web of Science ®Google Scholar
• LEEMAN, T. D., TRANSON, C., BONNABRY, P. and DAYER, P., 1993, A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Experimental and Clinical Research, 19, 189–195.
   PubMedGoogle Scholar
• LIN, J. H. and Lu, A. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetic, 35, 361–390.
   Google Scholar
• MAENPAA, J., SIGUSCH, H., RAUNIO, H., SYNGELMA, T., VUORELA, P., VUORELA, H. and PELKONEN, O., 1993, Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochemical Pharmacology, 45, 1035–1042.
   PubMed Web of Science ®Google Scholar
• MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JoyEux, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752–758.
   PubMed Web of Science ®Google Scholar
• MICHALETS, E. L. M., 1998, Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy, 18, 84–112.
   PubMed Web of Science ®Google Scholar
• MINERS, J. O., SMITH, K. J., ROBSON, R. A., McMANus, M. E., VERONESE, M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes: kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology, 37, 1137–1144.
   PubMed Web of Science ®Google Scholar
• MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., WRIGHT, E., HARMATZ, J. S. and SHADER, R. I., 1998, In vitro approaches to predict drug interactions in vivo. Biochemical Pharmacology, 55, 113–122.
   PubMedGoogle Scholar
• NAKAJIMA, M., YAMAMOTO, T., NUNOYA, K., YOKOI, T., NAGASHIMA, K., INouE, K., FUNAE, Y., SHIMADA, N., KAMATAKI, T. and KUROIWA, Y., 1996, Characterization of CYP 2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 1010–1015.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• PASTRAKULJIC, A., TANG, B. K., ROBERTS, E. A. and KALO W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Pharmacology, 53, 531–538.
   PubMed Web of Science ®Google Scholar
• RELLING, M. V, AOYAMA, T., GONZALEZ, F. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human P450 in the CYP 2C subfamily. Journal of Pharmacology and Experimental Therapeutics, 252, 442–447.
   PubMed Web of Science ®Google Scholar
• TANAKA, E., 1998, Clinically important pharmacokinetic drug—drug interactions: role of Cytochrome P450 enzymes. Journal of Clinical Pharmacology and Therapeutics, 23, 403–416.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., McMANus, M. E., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. O., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767–1776.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. and MINERS, J. O., 1993, VALIDATION OF 4NITROPHENOL AS AN in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochemical Pharmacology, 46, 1975–1981.
   PubMed Web of Science ®Google Scholar
• VERONESE, M. E., DOECKE, C. J., MACKENZIE, P. I., McMANus, M. E., MINERS, J. O., REES, D. L., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533–538.
   PubMed Web of Science ®Google Scholar
• YUN, H. Y., SHIMADA, T. and GUENGERICH, F. P., 1991, Purification and characterization of human liver microsomal cytochrome P-450 2A6. Molecular Pharmacology, 40, 679–685.
   PubMed Web of Science ®Google Scholar